BioSpace News Archive

Biomea Fusion, Inc. announced the full abstract, titled “BMF-219: A novel therapeutic agent to reestablish functional beta cells and provide long-term glycemic control”, will be presented during the Abstract Oral Presentation Session as well as the Poster Session of the 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease taking place in Los Angeles, California on December 7-9, 2023.

Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.

Hansa Biopharma, “Hansa”, announced positive high-level data from the 15-HMedIdeS-09 phase 2 trial that demonstrated imlifidase was safe and well tolerated when administered prior to standard of care, including rapid improvement in disease-related efficacy measures.

United Therapeutics, a public benefit corporation, announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024.

Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces First Patient First Visit (FPFV) in its Phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ innovative anti-TNFα biologic eye drop, for the treatment of Dry Eye Disease (DED).

KalVista Pharmaceuticals, Inc . today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA ® (pembrolizumab) Plus LYNPARZA ® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility.

Kymera Therapeutics, Inc. today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi.

Synlogic, Inc. announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU) has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.

Tilde Sciences, a specialty pharmaceutical company, announced today that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals.